司大勇(梁淑珍之子)

司大勇博士，1978年出生， 吉林大學生命科學學院\東北亞生物演化與環境教育部重點實驗室講師，哈佛大學醫學院訪問學者。司會武之孫，司兆光、梁淑珍之子。

主要研究領域為藥物代謝酶，在周慧教授的領導下，與鐘大放教授課題組合作，在國際上首先發現了CYP2C9*13的存在，此突變型之後在日韓也被發現；發現CYP2C9*13與CYP2C19*2存在一定連鎖關係；發現格列奇特由cyp2c19代謝，糾正了文獻報導的錯誤；還發現了黃酮類化合物對CYP2C9的廣泛的抑制作用；發現β1受體遺傳多態性對卡維地洛降壓療效有影響。

基本介紹

• 中文名：司大勇
• 國籍：中國
• 民族：漢族
• 出生日期：1978年
• 職業：講師
• 母親：梁淑珍
• 性別：男

學術論文發表

在國際著名刊物發表多篇學術論文，有一定影響：

Si Dayong, Guo Yingjie, Zhang Yifan, Yang Lei, Zhou Hui*, Zhong Dafang. Identification of a novel variant CYP2C9 allele in Chinese.Pharmacogenetics (Pharmacogenetics and Genomics). 2004 Jul;14(7):465-9.

Zhang Yifan, Zhong Dafang*, Si Dayong, Guo Yingjie, Chen Xiaoyan, Zhou Hui. Lornoxicam pharmacokinetics in relation to cytochrome P450 2C9 genotype. Br J Clin Pharmacol. 2005 Jan;59(1):14-7.

Guo Yingjie, Zhang Yifan, Wang Ying, Chen Xiaoyan, Si Dayong, Zhong Dafang, Fawcett JP, Zhou Hui*. Role of CYP2C9 and its variants (CYP2C9*3 and CYP2C9*13) in the metabolism of lornoxicam in human. Drug Metab Dispos. 2005 Jun;33(6):749-53.

Guo Yingjie, Wang Ying, Si Dayong, Fawcett PJ, Zhong Dafang, Zhhou Hui*. Catalytic activities of human cytochrome P450 2C9*1, 2C9*3 and 2C9*13. Xenobiotica 2005 Sep 1;35(9):853-861.

Zhang Yifan, Chen Xiaoyan, Guo Yingjie, Si Dayong, Zhong Dafang*, Zhou Hui. Impact of cytochrome P450 CYP2C9 variant allele CYP2C9*3 on the Pharmacokinetics of glibenclamide and Lornoxicam in Chinese subjects, 藥學學報 2005, 40(9):796-799

Zhou Yihan; Zheng Qingchuan; Li Zesheng*; Zhang Yuan; Sun Miao; Sun Chia-Chung; Si Dayong; Cai Lei; Guo Yingjie; Zhou Hui*,On the human CYP2C9 variant *13 activity reduction: a molecular, dynamics simulation and docking study, Biochimie, 2006 Volume 88, Issue 10, :1457-1465

Yifan Zhang, Dayong Si, Xiaoyan Chen, Nan Lin, Yingjie Guo, Hui Zhou, Dafang Zhong* Impacts of CYP2C9 and CYP2C19 genetic polymorphisms on pharmacokinetics of gliclazide MR in Chinese subjects, The British Journal of Clinical Pharmacology,2007 Jul;64(1):67-74.

Dayong Si, Ying Wang, Yi-Han Zhou, Yingjie Guo, Juan Wang, Hui Zhou*, Ze-Sheng Li, and J. Paul Fawcett，Mechanism of CYP2C9 Inhibition by Flavones and Flavonols ，Drug Metabolism and Disposition 2009 37: 629-634.

WANG Ying ZHOU Yi-han GUO Ying-jie XU Xue-lian SI Da-yong ZHOU Hui LI Ze-sheng, Role of Residue 90 in Catalysis of Cytochrome P450 2C9，CHEM. RES. CHINESE UNIVERSITIES 2009, 25(6), 904—908

Ruimei Yuan, XianweiZhang*, QianDeng,DayongSi,YuanWu,Feng Gao, and Biyun Zhou，TwoNovel SCN9A Gene HeterozygousMutationsMay Cause Partial Deletion ofPain Perceptionpme PainMedicine 2011; 12: 1510–1514

Hongjie Li, XinZhao, Yongbin Zhao, Chunxiang Li, DayongSi, HuiZhou and Yinqiu Cui，Genetic characteristics and migrationhistory of a bronze culture population in the West Liao-River valley revealedby ancient DNA，Journalof Human Genetics2011 Dec;56(12):815-22

Dayong Si, Juan Wang, Yifan Zhang, Dafang Zhong and Hui Zhou，Distribution of CYP2C9*13 allele in the Chinese Han and the long-range haplotype containing CYP2C9*13 and CYP2C19*2，Biopharmaceutics & Drug Disposition， 2012：2012 Sep;33(6):342-5.

Zhang M, Chen J, Si D, Zheng Y, Jiao H, Feng Z, Hu Z, Duan R. Whole exome sequencing identifies a novel EMD mutation in a Chinese family with dilated cardiomyopathy. BMC Med Genet. 2014 Jul 5;15(1):77.

張明秋 司大勇 焦海旭 張桂華 王娟，家族性擴張型心肌病家系基因篩查的研究，《中國實驗診斷學》2013年17卷09期1695頁

Si D, Wang J, Xu Y, Chen X, Zhang M, Zhou H. Association of common polymorphisms in β1-adrenergic receptor with antihypertensive response to carvedilol.J Cardiovasc Pharmacol. 2014 Oct;64(4):306-9

主持國家自然科學基金

81 10 25 08 和 兩項教育部自然科學基本科研業務費基金